WHO recommends against the use of convalescent plasma to treat COVID-19

Trials for severe and critical patients should continue

WHO has updated its living guideline on COVID-19 therapeutics to include convalescent plasma. For non-severe COVID-19 patients, WHO recommends against its use, while it should only be used within clinical trials for severe and critical COVID-19 patients.

Convalescent plasma is a transfusion of blood plasma from someone who has recovered from COVID-19.

Current evidence shows that convalescent plasma does not improve survival or reduce the need for mechanical ventilation, while it has significant costs.

An independent panel of experts, the guidelines development group, looked at pooled data from 16 randomized controlled trials, including 16 236 patients with non-severe, severe, and critical covid-19 infection.

While the evidence that convalescent plasma has no benefit in non-severe patients was certain, it was less so in the case of severe and critically ill patients. So, randomized clinical trials for these subgroups should continue.

This is the 7th update of WHO’s living guidelines on COVID-19 therapeutics. Read more about previous and upcoming recommendations on WHO’s website on therapeutics


Tags assigned to this article:

You may have an interest in also reading…

European Commission: Belgian Court orders AstraZeneca to deliver vaccine doses to the EU – Questions and Answers

Why did the European Commission start this Court proceeding and what did it intend to obtain? The company announced in

WHO: IOC joins forces with WHO and the United Nations to fight COVID-19

Athletes share messages to keep us #HEALTHYTogether On Olympic Day, 23 June 2020, the International Olympic Committee and WHO together

European Commission: Statement by President von der Leyen on vaccine sharing

Today, let me give you a few figures on vaccine sharing. The European Union is so far the biggest donor